Henan Lingrui Pharmaceutical Co., Ltd. Stock

Equities

600285

CNE000001501

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-07-17 EDT 5-day change 1st Jan Change
23.56 CNY +2.61% Intraday chart for Henan Lingrui Pharmaceutical Co., Ltd. -1.63% +37.70%

Financials

Sales 2024 * 3.75B 516M 707M Sales 2025 * 4.22B 581M 797M Capitalization 13.29B 1.83B 2.51B
Net income 2024 * 687M 94.52M 130M Net income 2025 * 810M 111M 153M EV / Sales 2024 * 3.54 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.15 x
P/E ratio 2024 *
19.4 x
P/E ratio 2025 *
16.5 x
Employees 2,530
Yield 2024 *
3.61%
Yield 2025 *
4.12%
Free-Float 77.13%
More Fundamentals * Estimated data
Dynamic Chart
Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Henan Lingrui Pharma Registers Chewable Asthma Drug in China MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million. CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021. CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news
1 day+2.61%
1 week-1.63%
Current month-2.68%
1 month-7.54%
3 months+2.08%
6 months+34.17%
Current year+37.70%
More quotes
1 week
22.78
Extreme 22.78
23.98
1 month
22.78
Extreme 22.78
25.70
Current year
16.15
Extreme 16.15
26.89
1 year
14.30
Extreme 14.3
26.89
3 years
9.57
Extreme 9.57
26.89
5 years
7.66
Extreme 7.66
26.89
10 years
6.81
Extreme 6.81
26.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 -
Director of Finance/CFO 55 -
Director/Board Member 51 -
Members of the board TitleAgeSince
Chief Executive Officer 40 -
Director/Board Member 60 06-04-17
Director/Board Member 55 23-05-17
More insiders
Date Price Change Volume
24-07-18 23.56 +2.61% 6,514,960
24-07-17 22.96 -1.80% 8,937,931
24-07-16 23.38 -1.60% 4,973,440
24-07-15 23.76 -0.34% 3,590,025
24-07-12 23.84 -0.46% 4,720,390

End-of-day quote Shanghai S.E., July 17, 2024

More quotes
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
23.56 CNY
Average target price
30.5 CNY
Spread / Average Target
+29.46%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600285 Stock